SignatureFD’s Vanda Pharmaceuticals VNDA Stock Holding History

SignatureFD’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.05K	Hold	499	–	–	﹤0.01%	3027
2026 Q1	$3.45K	Hold	499	–	–	﹤0.01%	2902
2025 Q4	$4.4K	Buy	+499	New	+$2.75K	﹤0.01%	2736
2024 Q4	–	Sell	-292	Closed	-$1.37K	–	3412
2024 Q3	$1.37K	Sell	292 -218	-43%	-$1.17K	﹤0.01%	2932
2024 Q2	$2.88K	Buy	+510	New	+$2.63K	﹤0.01%	2666
2024 Q1	–	Sell	-242	Closed	-$1.02K	–	3266
2023 Q4	$1.02K	Sell	242 -139	-36%	-$561	﹤0.01%	2901
2023 Q3	$1.65K	Sell	381 -2,422	-86%	-$13.5K	﹤0.01%	2826
2023 Q2	$18.5K	Buy	2,803 +2,381	+564%	+$15.3K	﹤0.01%	1930
2023 Q1	$2.87K	Buy	+422	New	+$2.97K	﹤0.01%	2700
2022 Q4	–	Sell	-71	Closed	-$1K	–	3418
2022 Q3	$1K	Buy	71 +27	+61%	+$285	﹤0.01%	3046
2022 Q2	$0	Buy	+44	New	+$456	﹤0.01%	3359
2022 Q1	–	Sell	-89	Closed	-$1K	–	3338
2021 Q4	$1K	Buy	+89	New	+$1.55K	﹤0.01%	3009

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SignatureFD's VNDA Position: Q2 2026 in Review

SignatureFD held its Vanda Pharmaceuticals (VNDA) position steady in Q2 2026 at 499 shares worth $3.05K. The position accounts for ﹤0.01% of the portfolio, ranked #3027.

SignatureFD first reported a position in VNDA in Q4 2021 and has held it in 12 quarters since. The position peaked at $18.5K in Q2 2023. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

SignatureFD held 499 shares of Vanda Pharmaceuticals worth $3.05K as of Q2 2026.
SignatureFD left its Vanda Pharmaceuticals share count unchanged in Q2 2026.
Vanda Pharmaceuticals made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #3027 holding.
SignatureFD first reported a position in Vanda Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
SignatureFD's Vanda Pharmaceuticals position peaked at $18.5K in Q2 2023.
172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.